Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Down 9.8% in February

Cryo-Cell International, Inc. (NYSEAMERICAN:CCELGet Free Report) was the target of a large decrease in short interest during the month of February. As of February 29th, there was short interest totalling 11,000 shares, a decrease of 9.8% from the February 14th total of 12,200 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 7,400 shares, the short-interest ratio is currently 1.5 days.

Institutional Trading of Cryo-Cell International

A number of institutional investors and hedge funds have recently made changes to their positions in CCEL. Vanguard Group Inc. increased its position in Cryo-Cell International by 8.7% during the 4th quarter. Vanguard Group Inc. now owns 91,139 shares of the company’s stock worth $524,000 after purchasing an additional 7,256 shares in the last quarter. Northern Trust Corp acquired a new position in Cryo-Cell International during the 4th quarter worth approximately $151,000. Finally, Cerity Partners LLC acquired a new position in Cryo-Cell International during the 4th quarter worth approximately $83,000. Institutional investors own 10.01% of the company’s stock.

Cryo-Cell International Stock Up 2.5 %

NYSEAMERICAN CCEL opened at $5.79 on Tuesday. The company has a market cap of $48.00 million, a P/E ratio of -5.08 and a beta of 0.41. Cryo-Cell International has a 12-month low of $2.69 and a 12-month high of $7.25. The firm has a 50-day simple moving average of $5.69.

Cryo-Cell International (NYSEAMERICAN:CCELGet Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.26 earnings per share (EPS) for the quarter. The firm had revenue of $7.88 million during the quarter. Cryo-Cell International had a negative net margin of 30.38% and a negative return on equity of 120.29%.

About Cryo-Cell International

(Get Free Report)

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.

See Also

Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.